Daily Sepsis Research Analysis
Analyzed 15 papers and selected 3 impactful papers.
Summary
Three sepsis-focused studies stood out: a robust pyroptosis-related 7-gene prognostic signature with external and single-cell validation; an integrative immunometabolic analysis linking lactylation-associated genes to sepsis with Mendelian randomization-supported protective loci; and a preclinical medicinal chemistry program yielding an anti-inflammatory lead (HSC-4) efficacious in murine sepsis and acute lung injury models.
Research Themes
- Pyroptosis-driven prognostic stratification in sepsis
- Immunometabolism and lactylation-linked gene networks in sepsis
- Translational anti-inflammatory therapeutics from medicinal chemistry to sepsis models
Selected Articles
1. Systematic characterization of pyroptosis-related gene patterns identifies potential prognostic inflammatory phenotypes in sepsis.
Using large public cohorts, the authors defined two sepsis molecular subtypes and derived a 7-gene pyroptosis-related score that predicted short-term mortality with strong performance, including external validation (AUC=0.984). High PRG-scores tracked immune remodeling (macrophage polarization, reduced CD8+ T cells, higher checkpoint expression) and remained elevated in non-survivors over time.
Impact: Provides a validated, mechanistically anchored prognostic signature and molecular subtyping framework that can guide risk stratification and hypothesis-driven immunomodulatory trials in sepsis.
Clinical Implications: The PRG-score could inform early risk stratification and identify patients likely to benefit from immunomodulation (e.g., checkpoint-targeted or macrophage-polarizing strategies), pending prospective validation and assay standardization.
Key Findings
- Consensus clustering of PRGs identified two sepsis subtypes; the inflammatory subtype had poorer prognosis.
- A 7-gene PRG-score (TUBG2, TNFAIP3, CXCL8, WFDC1, DEFA4, CX3CR1, ZBP1) predicted short-term mortality with AUCs >0.75 and external validation (GSE95233 AUC=0.984).
- High PRG-scores associated with increased M0/M2 macrophages, reduced CD8+ T cells, and higher CTLA4/TIGIT/IL-10; scores decreased over time in survivors but stayed high in non-survivors.
Methodological Strengths
- Multi-cohort development with external validation and strong discrimination.
- Integration of bulk and single-cell transcriptomics with immune infiltration analyses.
Limitations
- Retrospective analysis of public datasets; potential batch and selection biases.
- No prospective clinical validation or interventional testing of the signature.
Future Directions: Prospective, multicenter validation; development of a clinically deployable assay; testing signature-guided immunomodulatory strategies in interventional trials.
Sepsis is a life-threatening syndrome driven by a dysregulated host response to infection, yet reliable prognostic biomarkers remain limited. Pyroptosis has emerged as an important contributor to immune dysregulation in sepsis. Here, we systematically characterized pyroptosis-related gene (PRG) patterns using public transcriptomic cohorts (GSE65682). Consensus clustering identified two distinct molecular subtypes, with the poorer-prognosis subtype enriched in inflammatory pathways. Based on differentially expressed genes, we constructed a 7-gene PRG-score (TUBG2, TNFAIP3, CXCL8, WFDC1, DEFA4, CX3CR1, and ZBP1) via LASSO and Cox regression. This model demonstrated good predictive performance for short-term mortality (AUCs > 0.75), which was further evaluated in an independent septic shock cohort (GSE95233, AUC = 0.984). Single-cell RNA sequencing analysis (GSE167363) showed that PRG-scores tended to remain elevated in non-survivors but decreased over time in survivors. Immune infiltration analysis indicated that higher PRG-scores were associated with features of immune remodeling, including increased M0/M2 macrophage proportions, reduced CD8 + T cells, and higher expression of immune checkpoints (e.g., CTLA4, TIGIT) and IL-10. In addition, a prognostic nomogram integrating the PRG-score and age improved individualized survival estimation. Overall, these findings suggest that the 7-gene PRG-score may reflect immune status and is associated with prognosis, providing insights into molecular subtyping and potential immunomodulatory strategies in sepsis.
2. Lactate-Associated Gene Signatures as Predictors: A Comprehensive Analysis of Immune Profiles in Sepsis.
Integrating transcriptomics, Mendelian randomization, machine learning, and immune infiltration analyses, the study identified 138 lactylation-related sepsis genes and highlighted LYRM4 and MDC1 as protective loci with validation in GEO datasets and hospital patients. Findings link lactylation-associated signatures to immune cell profiles, supporting immunometabolic mechanisms in sepsis.
Impact: Introduces lactylation-linked predictors and uses genetic causal inference to prioritize protective genes, offering mechanistic targets and biomarker candidates in sepsis.
Clinical Implications: Potential development of assays for LYRM4 and MDC1 expression could aid risk stratification; lactylation pathways may represent therapeutic targets, pending functional validation and prospective studies.
Key Findings
- Identified 1,356 differentially expressed genes and 138 sepsis-related differentially expressed lactylation-related genes (Sepsis-DELRGs).
- Mendelian randomization suggested LYRM4 and MDC1 are protective against sepsis.
- Validation of MDC1 and LYRM4 expression was performed in GSE131761, GSE80496, and hospital sepsis patients; immune infiltration analyses linked these genes to immune cell profiles.
Methodological Strengths
- Integration of Mendelian randomization with transcriptomic differential expression and machine learning.
- External validation in multiple GEO datasets plus clinical patient samples.
Limitations
- Observational, dataset-driven analysis with potential confounding and batch effects.
- Functional mechanistic experiments are limited; MR instrument strength and pleiotropy assessments are not detailed in the abstract.
Future Directions: Functional validation of LYRM4 and MDC1 in sepsis models; development of lactylation-targeted interventions; prospective clinical validation of predictive signatures.
BackgroundSepsis is a complex disorder characterized by a dysregulated immune response to infection. Elevated lactic acid levels and lactylation modification may induce changes in gene expression and immune cell infiltration in sepsis.MethodsRNA-seq data and clinical information related to sepsis were obtained from GEO datasets. Differential expression analysis identified genes that are differentially expressed between sepsis patients and healthy controls. The lactylation-related genes were then integrated with the differential expressed genes to classify genes as Sepsis-related differentially expressed lactylation-related genes (Sepsis-DELRGs). Mendelian randomization analysis was performed to assess the causal relationship between Sepsis-DELRGs and the two groups. Machine learning algorithms predicted potential Sepsis-DELRGs, and immune infiltration analysis examined the relationships between these genes and immune cell types. Finally, we examined the expression of MDC1 and LYRM4 within the GSE131761 and GSE80496 datasets and in sepsis patients from our hospital.ResultsA total of 1356 differentially expressed genes were identified between sepsis patients and healthy controls. From these, 138 Sepsis-DELRGs associated with sepsis were isolated. Mendelian randomization identified LYRM4 and MDC1 as protective factors against sepsis. Both genes positively influence CD8
3. Design, synthesis, and biological evaluation of C-28 carboxyl derivatives of Hederacoside C as anti-inflammatory agents for acute lung injury.
Medicinal chemistry optimization of Hederacoside C at the C-28 carboxyl position yielded HSC-4, which showed significant anti-inflammatory efficacy in murine systemic sepsis and acute lung injury models with a favorable acute toxicity profile. The work targets hemolytic liability while preserving potency, positioning HSC-4 as a translational lead pending hemolysis and pharmacokinetic characterization.
Impact: Provides a rationally designed anti-inflammatory lead with in vivo efficacy in sepsis models, addressing a key liability (hemolysis) that has limited clinical translation of related saponins.
Clinical Implications: No immediate clinical change; HSC-4 supports a potential new anti-inflammatory approach for sepsis and acute lung injury, warranting comprehensive hemolysis testing, PK/PD profiling, and early-phase clinical evaluation.
Key Findings
- Rational design and synthesis of C-28 carboxyl derivatives to mitigate hemolytic toxicity of Hederacoside C.
- Lead compound HSC-4 showed significant anti-inflammatory efficacy in murine systemic sepsis and acute lung injury models.
- Acute toxicity testing up to 400 mg/kg over five days showed no significant hepatotoxicity or nephrotoxicity in mice.
Methodological Strengths
- Structure–activity–toxicity-informed rational design with iterative screening.
- In vivo validation across two disease models plus acute toxicity assessment.
Limitations
- Hemolytic activity reduction is inferred from design rationale; direct hemolysis assays not yet reported.
- Pharmacokinetic and pharmacodynamic properties remain uncharacterized; results limited to murine models.
Future Directions: Perform direct hemolysis testing, full PK/PD profiling, dose–response and survival studies in sepsis models, and GLP toxicology to support first-in-human evaluation.
Hederacoside C, a bioactive triterpenoid saponin isolated from the dried roots of the Ranunculaceae plant Pulsatilla chinensis, has demonstrated therapeutic efficacy in murine models of nephritis, acute lung injury, and inflammatory bowel disease. However, its further development as a drug candidate has been hampered by hemolytic toxicity and poor oral bioavailability. Based on published evidence that the free carboxyl group at the C-28 position is closely associated with hemolytic activity, a series of C-28 carboxyl derivatives was rationally designed and synthesized with the aim of attenuating hemolytic liability while preserving or enhancing anti-inflammatory potency. Following in vitro anti-inflammatory evaluation and cytotoxicity assessment, compound HSC-4 was identified as the most promising candidate for further in vivo pharmacological studies. Notably, HSC-4 exhibited significant anti-inflammatory efficacy in both a murine systemic sepsis model and an acute lung injury model. An acute toxicity study further demonstrated that HSC-4 did not cause significant hepatotoxicity or nephrotoxicity in KM mice at doses up to 400 mg/kg over five consecutive days. These findings suggest that HSC-4 represents a promising lead compound for the development of novel anti-inflammatory therapeutics, pending further hemolytic activity assessment and pharmacokinetic characterization.